Phase 1/2 JASPER Trial: Ruxolitinib Plus Enzalutamide for mCRPC

The JASPER trial is a phase 1/2 study launching from the University of Michigan, takes a fundamentally different approach to castration-resistant prostate cancer by targeting the molecular machinery driving cancer plasticity from the start: the JAK/STAT inflammatory signaling axis. Understanding why this strategy makes biological sense requires stepping into what we now know about how prostate cancers become plastic, why they resist the most powerful androgen receptor (AR) inhibitors, and why blocking JAK1/2 with ruxolitinib (combined with standard enzalutamide) is a real rational attempt to precision medicine.

Lineage plasticity does not emerge from nowhere. JAK/STAT signaling is not merely a passive bystander in plastic disease; it is a critical executor of the plasticity program itself. In elegant preclinical work using genetically engineered mouse models and patient-derived organoids, researchers demonstrated that epithelial cells expressing mixed luminal-basal characteristics (cells that are already partially dedifferentiated) require sustained JAK and fibroblast growth factor receptor (FGFR) activity to complete their transition into fully plastic, stem-like states. These plastic cells then acquire the capacity to express multiple lineage programs simultaneously: they can be AR-negative, neuroendocrine-like, and stem-like all at once.

The mechanism underlying this JAK-driven plasticity involves a coherent molecular logic. When prostate cancer cells face AR pathway pressure (from abiraterone, enzalutamide, or other AR inhibitors) they activate JAK/STAT signaling, particularly through STAT3 and STAT1 branches. IL-6, a pro-inflammatory cytokine found abundantly in the tumor microenvironment, drives this activation by binding to gp130, which recruits JAK proteins to phosphorylate and activate STAT molecules. Once phosphorylated, STAT3 and STAT1 translocate to the nucleus and activate an entire transcriptional program, one that includes genes driving cell proliferation, survival, angiogenesis, and immunosuppression. Crucially, STAT3 also binds to the IL-6 promoter itself, creating a self-amplifying positive feedback loop: more STAT3 activation leads to more IL-6 production, which drives more STAT3 activation.

Ruxolitinib, the same JAK1/2 inhibitor in JASPER, was tested in combination with docetaxel (a standard chemotherapy used in CRPC) in a panel of prostate cancer cell lines. The results were striking: ruxolitinib showed synergistic, not merely additive, suppression of AR-negative DU145 and PC3 cells when combined with docetaxel, with combination indices ranging from 0.25 to 0.71 (where values below 1 indicate synergy and below 0.5 indicate strong synergy). In contrast, in AR-positive LNCaP cells, the same combination showed only additive or antagonistic effects. This selectivity is important: it suggests that JAK inhibition works best in tumors that have already lost AR dependence, which is precisely the population JASPER is enrolling, men with lineage-plastic disease that has already become AR-insensitive. The mechanistic basis for this selectivity may relate to the fact that JAK/STAT signaling is particularly critical in AR-negative cells to drive proliferation and stem-like characteristics; in AR-positive cells that still rely on AR signaling for survival, JAK blockade alone is insufficient.

From a drug-development perspective, ruxolitinib brings important advantages as the JAK inhibitor for this trial. It is already FDA-approved and used chronically in myelofibrosis and polycythemia vera patients, so its safety profile is relatively well-mapped; common side effects include cytopenias (low blood counts) and infection risk, but these are manageable with appropriate monitoring.

Clinical trial.​